DE69435316D1 - Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren - Google Patents

Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren

Info

Publication number
DE69435316D1
DE69435316D1 DE69435316T DE69435316T DE69435316D1 DE 69435316 D1 DE69435316 D1 DE 69435316D1 DE 69435316 T DE69435316 T DE 69435316T DE 69435316 T DE69435316 T DE 69435316T DE 69435316 D1 DE69435316 D1 DE 69435316D1
Authority
DE
Germany
Prior art keywords
cells
retroviruses
preparation
highly efficient
efficient transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435316T
Other languages
English (en)
Inventor
Mitchell H Finer
Margo R Roberts
Thomas J Dull
Krisztina M Zsebo
Lu Qin
Deborah A Farson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GBP IP GREENWICH LLC
Original Assignee
GBP IP GREENWICH LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GBP IP GREENWICH LLC filed Critical GBP IP GREENWICH LLC
Application granted granted Critical
Publication of DE69435316D1 publication Critical patent/DE69435316D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69435316T 1993-06-11 1994-06-10 Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren Expired - Lifetime DE69435316D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/076,299 US5834256A (en) 1993-06-11 1993-06-11 Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
PCT/US1994/006667 WO1994029438A1 (en) 1993-06-11 1994-06-10 Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells

Publications (1)

Publication Number Publication Date
DE69435316D1 true DE69435316D1 (de) 2010-12-02

Family

ID=22131115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435316T Expired - Lifetime DE69435316D1 (de) 1993-06-11 1994-06-10 Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren

Country Status (10)

Country Link
US (3) US5834256A (de)
EP (1) EP0710280B1 (de)
JP (1) JP4409631B2 (de)
KR (1) KR100355423B1 (de)
AT (1) ATE485367T1 (de)
CA (1) CA2164835C (de)
DE (1) DE69435316D1 (de)
NZ (1) NZ269019A (de)
SG (1) SG55158A1 (de)
WO (1) WO1994029438A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9101680A (nl) 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
JPH08504095A (ja) * 1992-09-18 1996-05-07 カンジ，インコーポレイテッド 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法
US6051427A (en) * 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6506604B2 (en) * 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
EP0772689B1 (de) * 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Retrovirale vektoren mit verminderter rekombinationsrate
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
WO1996009400A1 (en) * 1994-09-19 1996-03-28 Systemix, Inc. Methods for genetically modifying hematopoietic stem cells
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
CA2216871A1 (en) * 1995-04-20 1996-10-24 Chiron Corporation High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US6017754A (en) * 1995-08-24 2000-01-25 Invitrogen Corporation System for isolating and identifying eukaryotic cells transfected with genes and vectors, host cells and methods thereof
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
PT880594E (pt) * 1996-01-23 2003-03-31 Oxford Biomedica Ltd Vector retroviral e sua utilizacao em terapia genica
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5766945A (en) * 1996-02-13 1998-06-16 Fred Hutchinson Cancer Research Center 10A1 Retroviral packaging cells and uses thereof
EP0953052B1 (de) * 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Rekombinationsunfähige retrovirale vektoren
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6083763A (en) * 1996-12-31 2000-07-04 Genometrix Inc. Multiplexed molecular analysis apparatus and method
US8703480B1 (en) * 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
CA2285666C (en) * 1997-03-21 2010-12-14 Enzo Therapeutics, Inc. Vectors and viral vectors, and packaging cell lines for propagating same
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
WO1999021977A1 (en) * 1997-10-24 1999-05-06 Life Technologies, Inc. Recombinational cloning using nucleic acids having recombination sites
US7294755B1 (en) * 1997-11-14 2007-11-13 Cedars-Sinai Medical Center Genetic modification of male germ cells for generation of transgenic species and genetic therapies
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20030039967A1 (en) * 1997-12-19 2003-02-27 Kris Richard M. High throughput assay system using mass spectrometry
US20030096232A1 (en) * 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
US20100105572A1 (en) * 1997-12-19 2010-04-29 Kris Richard M High throughput assay system
DE69933856D1 (de) 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
US6432686B1 (en) 1998-05-12 2002-08-13 E. I. Du Pont De Nemours And Company Method for the production of 1,3-propanediol by recombinant organisms comprising genes for vitamin B12 transport
US7074608B1 (en) 1998-05-12 2006-07-11 E. I. Du Pont De Nemours And Company Method for the production of 1,3-propanediol by recombinant organisms comprising genes for coenzyme B12 synthesis
US6678556B1 (en) * 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
IL127142A0 (en) * 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US6403784B1 (en) 1999-02-09 2002-06-11 Lexicon Genetics Incorporated Human uncoupling proteins and polynucleotides encoding the same
EP1849873B1 (de) * 1999-04-29 2011-10-12 Gbp Ip, Llc Verfahren und Mittel zur Herstellung von sicheren, rekombinanten Lentivirusvektoren mit hohem Titer
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1059356B1 (de) * 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replizierende retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
EP1059357A1 (de) * 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replizierende oder 'semi-replizierende' retrovirale Konstrukte, ihre Herstellung und Verwendungen für den Gentransfer
WO2001027274A1 (en) 1999-10-12 2001-04-19 Lexicon Genetics Incorporated Human ldl receptor family proteins and polynucleotides encoding the same
US6218186B1 (en) 1999-11-12 2001-04-17 Trustees Of The University Of Pennsylvania HIV-MSCV hybrid viral vector for gene transfer
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
US6790667B1 (en) 2000-05-30 2004-09-14 Lexicon Genetics Incorporated Human mitochondrial proteins and polynucleotides encoding the same
US7181416B2 (en) * 2000-06-08 2007-02-20 Blackstone Corporation Multi-function transaction processing system
US6852510B2 (en) * 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
EP1297168A2 (de) * 2000-07-03 2003-04-02 Gala Design, Inc. Expressionsvektoren
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20040185464A1 (en) * 2000-09-15 2004-09-23 Kris Richard M. High throughput assay system
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
DE60233047D1 (de) * 2001-05-14 2009-09-03 Gbp Ip Llc Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
US8216585B2 (en) * 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
JP2004537539A (ja) * 2001-06-29 2004-12-16 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ ヒトグロビン遺伝子をコードするベクターとその異常ヘモグロビン血症の治療におけるその使用
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
IL161229A0 (en) * 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
US20030148982A1 (en) * 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
PT1504108E (pt) 2002-02-01 2013-06-12 Oxford Biomedica Ltd Vetor lentiviral
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
CN100340668C (zh) * 2002-04-26 2007-10-03 国家健康医学研究所 改进的嵌合糖蛋白和假型化慢病毒载体
US6863884B2 (en) * 2002-05-01 2005-03-08 Cell Genesys, Inc. Pseudotyped retroviral vectors
EP1497437A4 (de) 2002-05-01 2005-11-16 Cell Genesys Inc Gegenüber komplement-inaktivierung resistente lentivirus-vektorpartikel
AU2003253992A1 (en) * 2002-07-18 2004-02-09 Robert P. Bennett Viral vectors containing recombination sites
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
WO2004048583A2 (en) * 2002-11-22 2004-06-10 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
EP1636360A4 (de) * 2003-06-03 2006-11-08 Cell Genesys Inc Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
CA2537953A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv in humans
DK1670925T3 (da) * 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
CA2545938A1 (en) * 2003-11-12 2005-05-26 Universite Laval High-titer retroviral packaging cells
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
ATE478965T1 (de) 2004-07-21 2010-09-15 Dana Farber Cancer Inst Inc Lentivirusvektoren und deren verwendung
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
AU2005287855B2 (en) 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
CN101506355B (zh) 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代（memp）及其应用
AU2006216671A1 (en) * 2005-02-23 2006-08-31 The Uab Research Foundation Alkyl-glycoside enhanced vaccination
ES2654428T3 (es) 2005-04-12 2018-02-13 Mesoblast, Inc. Aislamiento de células multipotenciales adultas por fosfatasa alcalina no específica de tejido
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
EP2468881A3 (de) * 2005-07-21 2012-08-15 Abbott Laboratories Mehrfache Genexpression mit sORF-Konstrukten und Verfahren mit Polyproteinen, Pro-Proteinen und Proteolyse
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
CN103113463B (zh) * 2005-12-13 2015-02-18 国立大学法人京都大学 核重新编程因子
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP1835032A1 (de) 2006-03-14 2007-09-19 Université de Liège Selbst-inaktivierender rekombinanter lentiviraler Vektor zur Inhibierung von HIV
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
WO2007124573A1 (en) * 2006-04-28 2007-11-08 Universite Laval High-titer retroviral packaging cells
AU2007353396C1 (en) * 2006-11-02 2013-06-27 Biomolecular Holdings Llc Hybrid immunoglobulins with moving parts
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
KR101688449B1 (ko) 2007-08-06 2016-12-21 메소블라스트, 아이엔씨. 생체 내에서 결합 조직을 생성, 복구 및/또는 유지하는 방법
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
EP3121597A1 (de) 2008-08-18 2017-01-25 Mesoblast, Inc. Monoklonaler antikörper stro-4
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
JP2013509188A (ja) * 2009-10-30 2013-03-14 アボット・ラボラトリーズ Ｓｏｒｆ構築物および複数の遺伝子発現
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011139688A2 (en) 2010-04-28 2011-11-10 The J. David Gladstone Institutes Methods for generating cardiomyocytes
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
SG10201504415YA (en) * 2012-03-13 2015-07-30 Emd Millipore Corp Use of centrifugation-aided infection to increase virus titer
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JP6901823B2 (ja) 2012-08-01 2021-07-14 ユナイテッド セラピューティクス コーポレイション 間葉系幹細胞による肺動脈性高血圧症の処置
EP3492084B1 (de) 2012-08-01 2021-02-17 United Therapeutics Corporation Behandlung von lungenarterienhochdruck mit prostacyclinbehandelten endothelvorläuferzellen
EP2895191B1 (de) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
ES2963968T3 (es) 2013-01-09 2024-04-03 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
US10471099B2 (en) 2013-05-10 2019-11-12 Whitehead Institute For Biomedical Research In vitro production of red blood cells with proteins comprising sortase recognition motifs
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2016164371A1 (en) 2015-04-07 2016-10-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods for inducing cell division of postmitotic cells
WO2017024000A1 (en) 2015-08-03 2017-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
CN109257926A (zh) 2016-03-18 2019-01-22 英特拉克森公司 用于治疗vii型胶原缺乏的组合物和方法
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3031994A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus
WO2018075623A1 (en) 2016-10-19 2018-04-26 The J. David Gladstone Institutes, A Testamentary Trust Etablished Under The Will Of J. David Gladst Genetically encoded cell death indicators and methods of use
AU2017350732B2 (en) 2016-10-24 2023-07-27 United Therapeutics Corporation Enhancement of MSC immunomodulatory properties by treprostinil
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
AU2017370640A1 (en) 2016-12-05 2019-07-18 The Regents Of The University Of California Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
EP3579870A4 (de) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Auf car-t-zell-tumor (ctct) abzielende phospholipidether (ple)-wirkstoffe
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
CN111918972A (zh) 2018-01-31 2020-11-10 朱诺治疗学股份有限公司 评估存在或不存在有复制能力的病毒的方法和试剂
SG11202102058UA (en) 2018-08-30 2021-03-30 Tenaya Therapeutics Inc Cardiac cell reprogramming with myocardin and ascl1
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
WO2021028837A1 (en) 2019-08-13 2021-02-18 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
CN114761546A (zh) 2019-10-08 2022-07-15 波士顿学院董事会 含有多个不同非天然氨基酸的蛋白质以及制备和使用此类蛋白质的方法
JP2023515672A (ja) 2020-03-02 2023-04-13 テナヤ セラピューティクス， インコーポレイテッド 心筋細胞発現マイクロｒｎａによる遺伝子ベクター制御
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
KR20230036061A (ko) 2020-04-27 2023-03-14 주노 쎄러퓨티크스 인코퍼레이티드 폴리에틸렌이민-디옥시리보핵산 복합체 크기 및 활성의 안정화
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
CN112458120B (zh) * 2020-11-25 2022-04-12 云舟生物科技(广州)股份有限公司 基于莫洛尼氏鼠白血病病毒的自失活载体及其应用
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
JP2024520797A (ja) 2021-06-08 2024-05-24 タッチライト・アイピー・リミテッド レンチウイルスベクター

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
WO1990002797A1 (en) 1988-09-15 1990-03-22 North Carolina State University Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same
WO1994019478A1 (en) * 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection

Also Published As

Publication number Publication date
KR100355423B1 (ko) 2003-04-03
US5686279A (en) 1997-11-11
US5834256A (en) 1998-11-10
SG55158A1 (en) 1998-12-21
KR960703169A (ko) 1996-06-19
JP4409631B2 (ja) 2010-02-03
AU699660B2 (en) 1998-12-10
AU7246294A (en) 1995-01-03
ATE485367T1 (de) 2010-11-15
EP0710280A1 (de) 1996-05-08
CA2164835A1 (en) 1994-12-22
NZ269019A (en) 2000-03-27
CA2164835C (en) 2010-01-05
US5858740A (en) 1999-01-12
JPH08511169A (ja) 1996-11-26
WO1994029438A1 (en) 1994-12-22
EP0710280A4 (de) 1999-04-28
EP0710280B1 (de) 2010-10-20

Similar Documents

Publication Publication Date Title
DE69435316D1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
WO1997007225A3 (en) High efficiency retroviral packaging system
Wagner et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors
Frecha et al. Strategies for targeting lentiviral vectors
US6190666B1 (en) DNA expression systems based on alphaviruses
US5616326A (en) Recombinant canine adenovirus 2 (CAV-2)
Suerth et al. Genetic modification of lymphocytes by retrovirus-based vectors
ATE211766T1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
JP2005502355A5 (de)
RU98101904A (ru) Рекомбинантный вирус mva и его использование
CA2298892A1 (en) Lentiviral vectors derived from sivagm, methods for their preparation and their use for gene transfer into mammalian cells
EP0512017A1 (de) Vakzine.
ATE120234T1 (de) Hiv-3-retrovirus und seine verwendung.
DE69936577D1 (de) Lentivirale Verpackungszellen
BRAND et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles
Yu et al. A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of hantaan virus induced protective immunity in mice
US6770283B1 (en) DNA expression systems based on alphaviruses
EP1156112B1 (de) Synthetische Gene für gagpol und deren Verwendungen
ES2683820T3 (es) Uso de proteínas GAG no de subtipo B para encapsidación lentiviral
DK0835137T3 (da) Indkapslede celler, som danner viruspartikler
Kobayashi et al. Translation initiation of a bicistronic mRNA of Borna disease virus: a 16-kDa phosphoprotein is initiated at an internal start codon
CA2873473C (en) Lentiviral vectors containing an mhc class i promoter
CA2392221A1 (en) Bovine immunodeficiency virus (biv) based vectors
Pfeiffer et al. Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы